<DOC>
	<DOCNO>NCT02077166</DOCNO>
	<brief_summary>This Phase 1b/2 study design ass safety efficacy ibrutinib combination lenalidomide rituximab subject relapsed/refractory Diffuse Large B-Cell Lymphoma ( DLBCL ) eligible transplant .</brief_summary>
	<brief_title>Ibrutinib Combination With Lenalidomide Rituximab Participants With Relapsed Refractory Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>Phase 1b : In dose escalation portion study , various cohort escalate dos lenalidomide may explore , use 3+3+3 principle dose determination . Phase 2 : This conducted international , multicenter , open-label study . Eligible subject receive ibrutinib , lenalidomide rituximab .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Pathologically confirm relapsed/ refractory DLBCL Must previously receive first line treatment regimen Must ineligible high dose therapy/ stem cell transplantation Measurable disease sit CT scan ( &gt; 1.5 cm long dimension ) PT/INR &lt; 1.5 x ULN PTT ( aPTT ) &lt; 1.5 x ULN Men woman â‰¥18 year age ECOG &lt; 2 Adequate hepatic renal function Adequate hematologic function Medically apparent central nervous system lymphoma leptomeningeal disease History allogeneic stemcell ( organ ) transplantation Any chemotherapy , external beam radiation therapy , anticancer antibody within 2 week Radio toxinimmunoconjugates within 10 week Concurrent enrollment another therapeutic investigational study previously take ibrutinib and/or lenalidomide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>DLBCL</keyword>
</DOC>